SCHEMBL30294337

SCHEMBL30294337

CC(C)c1cc(F)ccc1Nc1cc(C(F)(F)F)ccc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 3/20 0.51
MPO P05164 4/20 0.50
GRIK1 P39086 2/20 0.47
AKR1C3 P42330 3/20 0.45
AKR1C2 P52895 3/20 0.45
AKR1B1 P15121 1/20 0.45
AKR1C4 P17516 1/20 0.45
AKR1C1 Q04828 1/20 0.45
ACLY P53396 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
LIPC P11150 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
USP2 O75604 1/20 0.41
CYP2C19 P33261 1/20 0.41
CLCN2 P51788 1/20 0.41
KDM1A O60341 1/20 0.41
KCNK2 O95069 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852871 0.91 MPO (0.57) TAS2R14MPOGRIK1AKR1C3AKR1C2
SCHEMBL30294370 0.91 MPO (0.57) TAS2R14MPOGRIK1AKR1C3AKR1C2
SCHEMBL30294460 0.88 CLCN2 (0.50) MPOGRIK1AKR1C3AKR1C2AKR1B1
SCHEMBL22852848 0.88 CLCN2 (0.50) MPOGRIK1AKR1C3AKR1C2AKR1B1
SCHEMBL30294715 0.84 KDM4E (0.42) TAS2R14MPOKDM4ECYP2C19
SCHEMBL22853359 0.84 KDM4E (0.42) TAS2R14MPOKDM4ECYP2C19
SCHEMBL22853007 0.84 CLCN2 (0.46) GRIK1AKR1C3AKR1C2ACLYCLCN2
SCHEMBL30294254 0.84 CLCN2 (0.46) GRIK1AKR1C3AKR1C2ACLYCLCN2
SCHEMBL22833402 0.84 TAS2R14 (0.61) TAS2R14MPOGRIK1AKR1C3AKR1C2
SCHEMBL29380178 0.84 TAS2R14 (0.61) TAS2R14MPOGRIK1AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B TAS2R14 1406/4885MPO 3074/4885GRIK1 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.